Loading
A phase 3 trial of Elranatamab, Daratumumab, Pomalidomide in multiple myeloma, run by Pfizer, now recruiting.
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments is a phase 3 interventional study registered as NCT05020236 by Pfizer, with 893 participants planned, started 2021-10-04 and due to reach its primary completion in 2026-02-26. Interventions recorded: Elranatamab, Daratumumab, Pomalidomide, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Dexamethasone.
Shares Elranatamab, Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Dexamethasone.
Shares Elranatamab, Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Dexamethasone.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Dexamethasone.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Elranatamab, PROTACs & molecular glues (targeted protein degradation), Pfizer (incl. Seagen), T-cell engagers (bispecific).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/